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Abstract
Background: Poor clinical record keeping hinders health systems monitoring and patient care in many low resource
settings. We develop and validate a novel method to impute dates of antiretroviral treatment (ART) initiation from
routine laboratory data in South Africa’s public sector HIV program. This method will enable monitoring of the national
ART program using real-time laboratory data, avoiding the error potential of chart review.
Methods: We developed an algorithm to impute ART start dates based on the date of a patient’s “ART workup”, i.e. the
laboratory tests used to determine treatment readiness in national guidelines, and the time from ART workup to
initiation based on clinical protocols (21 days). To validate the algorithm, we analyzed data from two large clinical HIV
cohorts: Hlabisa HIV Treatment and Care Programme in rural KwaZulu-Natal; and Right to Care Cohort in urban
Gauteng. Both cohorts contain known ART initiation dates and laboratory results imported directly from the National
Health Laboratory Service. We assessed median time from ART workup to ART initiation and calculated sensitivity (SE),
specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) of our imputed start date vs. the true
start date within a 6 month window. Heterogeneity was assessed across individual clinics and over time.
Results: We analyzed data from over 80,000 HIV-positive adults. Among patients who had a workup and initiated ART,
median time to initiation was 16 days (IQR 7,31) in Hlabisa and 21 (IQR 8,43) in RTC cohort. Among patients with
known ART start dates, SE of the imputed start date was 83% in Hlabisa and 88% in RTC, indicating this method
accurately predicts ART start dates for about 85% of all ART initiators. In Hlabisa, PPV was 95%, indicating that for
patients with a lab workup, true start dates were predicted with high accuracy. SP (100%) and NPV (92%) were also
very high.
Conclusions: Routine laboratory data can be used to infer ART initiation dates in South Africa’s public sector. Where
care is provided based on protocols, laboratory data can be used to monitor health systems performance and improve
accuracy and completeness of clinical records.
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Background
In many low- and middle-resource settings, clinical re-
cords are often incomplete, missing, and/or poorly ar-
chived [1]. Where patient records are hand-written,
implementation and maintenance of electronic records
can be expensive and still not impervious to error [2–4].
Accurate clinical record keeping is increasingly import-
ant to clinical care and appropriate monitoring and
evaluation in such settings [5]. Many developing country
health systems were set up to provide maternal services,
vaccinations, and acute care for injury and infections.
However, the rising global burden of chronic disease re-
quires health systems to manage patients’ health longitu-
dinally, a challenge in the absence of accurate clinical
information. Information gaps also make it difficult to
monitor large health care programs and allocate re-
sources optimally [6]. Improved record keeping from
treatment sites or cohorts is particularly challenging in
settings of high patient mobility across sites, providers,
and sectors (public/private), and yet it is precisely in
such settings that complete and accurate records are
critical to the coordination of patient care [1, 3, 7].
For many diseases, laboratory testing is a meticulously
specified element of clinical protocols, as it is the basis
for many diagnostic and treatment decisions in low-
resource settings. Laboratory tests are often conducted
off-site at central laboratories and test results may be
available directly from the laboratories, bypassing two
steps prone to human error: manual entry of data into
patient charts and manual transcription of chart infor-
mation into electronic databases. Where data from rou-
tine laboratory tests are systematically available, such
information may be used to impute missing data in clin-
ical records.
As with other chronic diseases, HIV/AIDS requires
lifelong clinical management and decision-making
guided by routine laboratory monitoring. South Africa
has the largest number of people living with HIV/AIDS
worldwide, with 7 million adults living with HIV in 2015
[8] and approximately half of these receiving antiretro-
viral therapy [9]. According to South African national
ART treatment guidelines [10–12], patients initiating
ART should have certain laboratory tests conducted
prior to starting treatment, hereafter referred to as “ART
workup”. Clinicians use this combination of blood tests
to assess liver function, anemia, and other factors. This
allows the clinician to accurately stage the patient’s dis-
ease, treat any co-morbid conditions, and guide the
choice of treatment regimen.
We propose using routine laboratory data from South
Africa’s National Health Laboratory Service (NHLS) to
impute dates of antiretroviral treatment (ART) initiation
among patients in South Africa’s public sector HIV care
and treatment program. South Africa has detailed
national guidelines for initiation of HIV care and treat-
ment [10–12] (Fig. 1). Following a positive result from
an HIV test, a CD4 count test is done to determine im-
mune function and, historically, eligibility for initiation
of ART. As of September 2016, all patients are eligible
for ART at diagnosis, but CD4 counts are still done at
enrollment. Once eligibility and intent to initiate is
established, the ART workup blood tests are conducted
to guide regimen choice. Patients then attend approxi-
mately three once-weekly counseling and preparatory
sessions before initiating ART (under guidelines during
the study period). We thus proposed to impute ART
start dates by identifying ART workup dates and adding
21 days. To determine the success of the approach we
assessed its validity with respect to sensitivity, specificity,
positive predictive value, and negative predictive value.
Sensitivity refers to the proportion of true ART start
dates accurately identified using our approach. Con-
versely, positive predictive value captures the proportion
of imputed start dates that accurately identify a true start
date. Specificity and negative predictive value describes
the accuracy of our approach in identifying non-
initiators.
NHLS provides laboratory services to all public-sector
facilities in South Africa (the province of KwaZulu-Natal
joined NHLS in 2010), including all laboratory testing
required for ART monitoring with over 26 million CD4
counts and 13 million viral loads resulted between 2004
and 2015. If successful, our imputation approach has the
potential to improve the capabilities of laboratory data
to monitor and evaluate South Africa’s national HIV care
and treatment program.
Methods
Data sources and study population
To assess the feasibility and validity of imputing ART
start dates from ART workup dates, we analyzed data
from two large clinical research cohorts with known
dates of ART initiation that are already integrated with
the NHLS database [13, 14]. The Hlabisa HIV Treat-
ment and Care Programme Cohort is a rural public sec-
tor ART program that includes all HIV patients
initiating ART at 17 primary health care clinics and
one sub-district hospital in rural Hlabisa sub-district
of KwaZulu-Natal province since mid-2004. Since 1
January 2007, the Hlabisa Cohort has systematically
collected data on all HIV patients receiving pre-ART
care, including those who never go on to initiate
ART, one of the few large South African cohorts to
do so. Chart-based data on dates of ART initiation
were available in the Hlabisa Cohort through the end
of 2012. The Right to Care (RTC) Clinical Cohort in-
cludes all HIV patients initiating ART at seven RTC-
supported primary health care clinics and one provincial
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hospital in urban and peri-urban settings in Gauteng
province. Patients do not routinely enter the database
until they initiate ART, at which point data prior to ART
initiation is entered retrospectively. All data, including
demographic, clinical conditions, laboratory test results
and medications (ART and non-ART related) are entered
into an electronic patient management and decision sup-
port system (TherapyEdge-HIV™). The selection of these
cohorts reflects the wide diversity of settings in which care
is provided in South Africa’s public sector: urban vs. rural,
hospital-based vs. clinic-based. Ethical clearance to
analyze data from these cohorts was granted by the Hu-
man Research Ethics Committee of the University of the
Witwatersrand as well as the Boston University Institu-
tional Review Board.
For both cohorts, data on laboratory tests — in-
cluding CD4 counts, viral loads, and the ART work-
up tests — are electronically integrated directly from
the NHLS as results become available, rather than be-
ing captured retrospectively from charts or paper re-
cords. As all laboratory data in the NHLS database
(which contains no information on date of ART initi-
ation) is also in the clinical databases of the Hlabisa
and Right to Care cohorts, which do contain data on
date of ART initiation, we validated our method (de-
scribed below) for imputing ART initiation date from
laboratory data in each of these clinical cohorts. Our
analysis included all patients in the Hlabisa Cohort
who had an ART workup or initiated ART between 1
January 2007 and 31 December 2012; and all patients
in the RTC cohort who initiated ART between 1
January 2005 and 31 December 2014. Since we were
interested in patients’ date of ART initiation, we ex-
cluded patients identified as having transferred into
the cohorts after having previously initiated ART
elsewhere.
Imputed ART initiation dates using laboratory data
During the period 2004-2014, guidelines required, at a
minimum, testing of hemoglobin (Hb) and alanine trans-
aminase (ALT) as part of the ART workup. We thus de-
fined an ART workup date as the date of a patient’s first
documented Hb or ALT among patients with a CD4
count in the previous 12 months prior to, or in the
month following, the ART workup date. Patients without
a previous CD4 count were not coded as having had an
ART workup because they may have received Hb or
ALT tests as part of investigations for other clinical con-
ditions (e.g. anemia or liver dysfunction respectively).
Though the frequency of Hb/ALT without a prior CD4
is relatively low in the HIV cohorts we analyzed, it may
be more common in other settings; including CD4
counts enables application of our approach to settings
(such as the full NHLS database) where patients' HIV
status is not always known. The requirement of a CD4
count may reduce the sensitivity of our approach, as
some patients are initiated on ART without a prior re-
corded CD4 count; we thus present sensitivity analyses
excluding the prior 12-month CD4 criterion. As de-
scribed previously, the three once-weekly counseling ses-
sions between ART workup and ART initiation generate
an interval of approximately three weeks between an
ART workup and ART initiation (Fig. 1). Therefore, ap-
plying this assumption, we imputed ART start dates by
adding 21 days to the date of a patient’s lab work-up.
Known dates of ART initiation in the Hlabisa and Right to
Care cohorts
The Hlabisa and Right to Care cohorts contain known
dates of ART initiation that are collected systematically
from electronic clinical records. Known date of initiation
is defined as the earliest date when a triple-drug ART
regimen was dispensed. Dates of initiation are recorded
Fig. 1 Visit schedule prior to ART initiation under treatment protocols during the study period
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in the databases as the date when pills are first dispensed
based on prescription chart data. This information is
then extracted from clinical records by trained data
clerks and input into the RTC and Hlabisa databases. Al-
though it is possible that in some cases, the date of initi-
ation was entered incorrectly, because patients return
for care weekly and then monthly after starting ART, it
is unlikely that dates of initiation were more than a week
or two off.
Validation of imputed ART start dates
Though ART guidelines are applied nationally, there
could be variation in degree of adherence to them due
to individual facility circumstance and prevailing clinical
protocols. Therefore, we undertook two validation exer-
cises to assess the performance of our imputed ART
start dates relative to actual known dates of ART initi-
ation in the Hlabisa and RTC cohorts. First, to test the
assumption of 21-days between ART workup and ART
initiation that we used to impute ART start date created
with the laboratory data, we set out to describe the dis-
tribution of times from ART workup to known ART ini-
tiation in the clinical cohorts. Restricting our sample to
patients with both an ART workup date and a known
ART start date, we calculated the number of days from
the ART workup date to the known ART start date.
Stratifying by cohort, we described the cumulative dens-
ity function (CDF) of the distribution graphically and
calculated the median and other percentiles of the distri-
bution. Additionally, we assessed variation in the median
time from work-up to ART initiation across different
clinic sites and over time.
Second, we evaluated the performance of our algo-
rithm for imputed ART start dates using traditional test
performance criteria. Using the known dates of ART ini-
tiation as the gold standard, we calculated the sensitivity,
specificity, positive predictive value, and negative pre-
dictive value of our imputed ART start dates. We con-
sider our imputed start date as a “match” to the known
ART start date if the imputed start date was within a
six-month window period of the known ART start date.
Six months was selected as the initial cutoff period as
clinical care in these settings mandates a CD4 count re-
sult is only valid for determining ART eligibility for a
period of six months from the test date after which it
must be repeated. Based on the shape of the distribution
assessed in the first validation exercise (the long right
tail), an asymmetric window was chosen. The six-month
window period to determine a match (matching window
period) began on the date of the ART workup (equiva-
lent to imputed start date minus 21 days) and extended
six months later (equivalent to imputed start date plus
161 days).
Sensitivity of the imputation approach was defined as
the probability that a patient who truly initiated ART
had an ART workup in the matching window period and
thus had an accurate imputed ART start date. Sensitivity
can be interpreted as the proportion of ART start dates
that would be accurately identified using information
only on ART laboratory work-up dates. We estimated
sensitivity separately for each of the cohorts and across
clinics and years within each cohort. As complete pre-
ART data are necessary to calculate positive as well as
negative predictive value and specificity, we limited these
analyses to the Hlabisa cohort. Positive predictive value
(PPV) of the imputation approach was defined as the
proportion of patients with an ART workup that truly
initiated ART within the matching window period. Spe-
cificity of the imputation approach was defined as the
probability that a patient who truly did not initiate ART
also did not have an ART workup. Because patients who
did not initiate ART had no date from which to estimate
a six-month window, specificity was assessed as the
probability of never having had a work-up conditional
on never having initiated ART by the end of follow-up.
Similarly, negative predictive value (NPV) was defined as
the probability that a patient who was diagnosed with
HIV and had a CD4 count but never had an ART
workup also never initiated ART during follow-up.
Results
We analyzed data on 57,401 patients in the Hlabisa
Cohort; 38% (n = 21,766) of these had a documented
ART initiation date in the clinical database while 33%
(n = 18,836) had a documented ART workup. An add-
itional 493 (0.9%) had an Hb/ALT result without a
CD4 count. Currently, the RTC cohort contains data
on over 133,000 patients, of whom 102,070 have initi-
ated ART. Of these, we analyzed the 69,283 (68%)
with a documented ART initiation date, of whom
63,914 (92%) had a documented ART workup and an
additional 1153 (1.6%) had an Hb/ALT without a
CD4 count. The cohorts were similar with respect to
age and gender distribution while those in the RTC
cohort initiated at slightly lower CD4 counts (median
123 vs. 152 cells/mm3) compared to those in the Hlabisa
cohort (Table 1).
We calculated the number of days from the ART
workup date to the known date of ART initiation for
each patient (Fig. 2). Very few patients (2.5% in the
Hlabisa Cohort, 4.4% in the RTC cohort) had their first
recorded ART workup after ART initiation. These pa-
tients may have transferred into care and not been iden-
tified as such in the cohort dataset. The vast majority
of patients who initiated ART did so after the workup
date and 95% of patients in both the Hlabisa Cohort
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and RTC cohorts who initiated ART did so within
91 days after the ART workup. The median interval
from ART workup to ART initiation was 16 days
(IQR 7 – 31) in the Hlabisa cohort and 21 days (IQR
8 – 43) in the RTC cohort.
Median times from lab workup to ART initiation in
the two cohorts were not only very similar to each other
but also remarkably close to our hypothesized interval of
21 days from ART workup to initiation based on the ini-
tiation process outlined in national guidelines. While
this suggests that, in general, sites implement procedures
as outlined in the guidelines, practices could vary con-
siderably by facility. We thus stratified this analysis by
each of the facilities contributing data towards the larger
Hlabisa and RTC cohorts. While there was some variation
in the median number of days from ART workup to initi-
ation between certain sites and we could not conclude
there was no clinic-level variation, the overall consistency
of the interval between workup and ART start dates by
site was reassuring (Additional file 1: Table S1).
We also considered that there might be an association
between calendar year and time from workup to treat-
ment initiation as treatment guidelines have evolved
somewhat over time and clinics may have become more
efficient at initiating eligible patients as the rollout of the
treatment program matured. We stratified the median
number of days to initiation by calendar year and noted
a decreasing trend in the number of days to initiation
over our period of study (Additional file 1: Table S2).
This decrease in the interval to initiation was remarkably
similar for both cohorts and consistent with known pro-
grammatic changes in the treatment initiation guidelines
towards faster ART initiation. Of note, 2008 PMTCT
guidelines mandated that all pregnant women should be
fast-tracked on ART [15], though no exact timeline was
stipulated and clinic-level implementation may have
been formalized somewhat later. In 2010, updated guide-
lines specified that pregnant women, patients with drug-
resistant tuberculosis, and patients with nadir CD4 cell
counts <100 cells/mm3 should be fast-tracked onto ART
within 2 weeks of determining eligibility [11]. In 2012,
fast-tracking was further expanded to include initiation
within 2 weeks for those with CD4 counts < 350 cells
and same-day initiation for those with CD4 counts <200
and all pregnant women regardless of CD4 count (Com-
munication, National Department of Health, 2012).
Thus, while workup date plus 21 days is a reasonable es-
timate for dates of initiation historically, analyses of pa-
tients initiating ART in more recent years and in the
future might consider downward revisions to the 21-day
interval. We note that differences of 2-3 weeks are un-
likely to affect most analyses, and indeed our estimates
of sensitivity, specificity, and positive and negative pre-
dictive values were virtually unchanged when imputing
using the estimated annual median time to initiation in
place of the 21-days value.
Having established 21-days as a reasonable estimate of
time to initiation for patients with both workup dates
and ART start dates, we turned to an assessment of the
validity of using workup date plus 21 days to impute
ART start dates. We estimated the sensitivity of our im-
puted start date for each of the cohorts based on
whether the imputed date was considered a “match” to
the known start date as defined above. Our results dem-
onstrated high sensitivity of the imputed date. Among
those with known ART start dates, very similar propor-
tions (82.6% in Hlabisa and 88.2% in RTC) had a
matched imputed start date (Table 2), indicating this
Table 1 Demographic and clinical features of 90,281 patients at
ART initiation in the Hlabisa and Right to Care cohorts in South
Africa
Hlabisa Cohorta RTC Cohortb
(n = 21,766) (n = 69,283)
Gender % male 7421 (34.1%) 25902 (37.4%)
Age at initiation (years) <18 2092 (9.6%) 3390 (4.9%)
18-29 6369 (29.3%) 15470 (22.3%)
30-39 7294 (33.5%) 28286 (40.8%)
40-49 3880 (17.8%) 15334 (22.1%)
> = 50 2125 (9.8%) 6803 (9.8%)
Median (IQR) 33 (26, 41) 35 (29, 42)
CD4 count (cells/mm3)
at initiation
0-49 3282 (16.1%) 15228 (22.0%)
50-99 3220 (15.8%) 10699 (15.4%)
100-199 7567 (37.0%) 19795 (28.6%)
200-349 4818 (23.6%) 11346 (16.4%)
> = 350 1540 (7.5%) 4178 (6.0%)
Missing 1339 (6.2%) 8037 (11.6%)
Median (IQR) 152 (78, 226) 123 (50, 201)
Year of ART initiation 2005 n/a 2975 (4.3%)
2006 n/a 5339 (7.7%)
2007 1963 (9.0%) 6530 (9.4%)
2008 3467 (15.9%) 8612 (12.4%)
2009 3223 (14.8%) 10546 (15.2%)
2010 3723 (17.1%) 11036 (15.9%)
2011 4607 (21.2%) 8325 (12.0%)
2012 4783 (22.0%) 6744 (9.7%)
2013 n/a 5457 (7.9%)
2014 n/a 3719 (5.4%)
aHlabisa Cohort includes all HIV patients with a first CD4 count in care
between 1 January 2007 and 31 December 2012 at 17 clinics and one
sub-district hospital in Hlabisa, KwaZulu-Natal. Data in this table are restricted
to patients who initiated ART. Hlabisa Cohort also includes patients who
presented for care but never initiated ART. Total sample size in the Hlabisa
Cohort was 57,401 of whom 21,766 initiated ART
bRTC Cohort includes all patients who initiated ART between 1 Jan 2005 and
31 December 2014 at 8 sites supported by Right to Care in Gauteng Province
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imputation method will correctly estimate the ART start
date as defined within a 6 month window period for
roughly 85% of those who initiated ART. The sensitivity
of our imputation approach was consistently high over
time ranging from 78 to 93% over the 10 calendar years
evaluated (Additional file 1: Table S2), and across facil-
ities, ranging from 77 to 97% in all but two sites
(Additional file 1: Table S1).
Next, we restricted the analysis to the Hlabisa cohort
and evaluated the PPV, NPV, and specificity (Table 3).
Among all patients with an ART workup — including
those that never initiated — the probability that a pa-
tient went on to initiate ART within the six-month win-
dow was PPV= 95.4%, implying that fewer than 5% of
patients with an ART workup would be falsely identified
as initiating ART using our imputation strategy. Specifi-
city and NPV were also both high (99.8% and 92.2% re-
spectively). Sensitivity and NPV increased slightly after
removing the requirement of a CD4 count in the pre-
vious 12 months from the definition of an ART
workup (Tables 2 and 3, rightmost column).
As highlighted previously, we used a guideline-driven
initial window period of 6 months to define a “matching”
period for the imputed initiation dates. However, this
period is arbitrary, and as we show in Fig. 2, the vast
majority of patients initiated within a much shorter win-
dow. We thus created several alternate matching win-
dow periods varying from 1 month to 9 months and
estimated sensitivity of the imputation approach with
these changes in window period (Additional file 1: Table
S3). Sensitivity dropped to about 60% when the window
was restricted to one month but was over 80% at 3, 6,
and 9 months.
Discussion
Our analysis has a number of implications. The results
provide guidance on whether the date of an ART
workup can be used to infer dates of ART initiation in
South Africa, and with what degree of certainty. We
demonstrate high sensitivity and high positive predictive
value of this approach, and performance appears to be
consistent across diverse geographic and facility settings
and over time. Laboratory-imputed initiation dates could
be used as part of an effort to create a national clinical
cohort from laboratory databases such as the NHLS (i)
to monitor and evaluate South Africa’s ART program
and (ii) to improve clinical records, patient care and
Table 2 Sensitivity of imputation method in Hlabisa and RTC
cohorts
Hlabisa Cohort: Sensitivity Truly initiated ART = yes
HGB/ALT + CD4 HGB/ALT only
ART workup in 6mo prior
to known ART start date?
Yes 17,970 18,393
No 3,796 3,373
Total 21,766 21,766
Sensitivity 82.6% 84.5%
RTC Cohort Sensitivity Truly initiated ART = yes
HGB/ALT + CD4 HGB/ALT only
ART workup in 6mo prior
to known ART start date?
Yes 61,105 61,632
No 8,178 7,651
Total 69,283 69,283
Sensitivity 88.2% 89.0%
Fig. 2 Time from ART workup date to known ART initiation date Fig. 2a displays the cumulative distribution for Hlabisa; Fig. 2b displays the
cumulative distribution for Right to Care. In the Hlabisa Cohort, 2.3% of patients with an ART workup had initiation dates more than 182 days
later or had not initiated by the end of follow-up. As this population was not observed in the RTC cohort, patients initiating more than 182 days
or not at all are excluded from both plots
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accountability at all levels of the healthcare system. The
implications for the evaluation of South Africa’s national
program could be significant. The ability to impute dates
of initiation within the national NHLS database will en-
able evaluation of key aspects of the national program,
providing strong evidence (in a resource efficient man-
ner) beyond what existing surveillance systems and co-
hort estimates have been able to do to date. These data
could also be used to monitor facility performance and
to improve accountability, although vigilance is required
against the possibility of adverse behavioral conse-
quences (e.g., conducting unnecessary Hb/ALT tests to
boost numbers).
Laboratory testing is used routinely in determining
HIV disease progression a nd assessing ART eligibility
(historically), determiningART regimen, and monitoring
patients on therapy in many southern African countries,
though the specific protocols for how laboratory testing
is used vary across countries and coverage is uneven
[16–23]. Although our approach — imputing clinical
data using laboratory results — may have broad applic-
ability, the specific imputation algorithms used may dif-
fer in other countries and will have to be validated in
those contexts. Our analysis yields a validated algorithm
for South Africa and a proof of concept that could be
applied in other countries, particularly as laboratory in-
frastructure improves.
Our findings also have implications for understanding
the continuum of HIV care and treatment. Although sig-
nificant losses have been described between HIV testing
and ART initiation both in the Hlabisa cohort [24] and
elsewhere [25], our results on positive predictive value
imply that the losses from date of ART work-up to ART
initiation are modest. This implies that losses to initi-
ation are occurring primarily within the first few
clinic visits, between HIV testing and collection of
workup bloods. Future interventions could target
these early stages in the cascade of care, where most
attrition occurs.
The methods described here to leverage routinely col-
lected laboratory data may have other applications. First,
improving the accuracy and completeness of clinical re-
cords may be an important and cost-effective step in
overcoming obstacles to effective chronic disease man-
agement in low resource settings. Integration of labora-
tory data into clinical records could help manage highly
mobile patient populations. Second, this methodology
may offer several opportunities to enhance existing
monitoring and evaluation strategies. Laboratory data
could be used to triangulate against aggregate (e.g.
district-level) information on new ART initiates based
on clinic reporting. Because sensitivity is lower than
PPV, the number of ART workups is expected to be
lower than the number of ART initiators. However, the
number of ART initiators can be estimated easily by
multiplying the number of workups in a given popula-
tion by a factor equal to PPV/sensitivity, equal to 1.15 in
the Hlabisa cohort.1 Of course, the generalizability of
this adjustment factor depends on the generalizability of
our sensitivity and PPV estimates. In settings where na-
tionally complete registration data is not available, link-
ages between various sources of “big” data can
significantly improve monitoring disease burden and
health system response. South Africa has a national vital
registration system, the National Population Register,
and linkages between this register and several HIV co-
horts have successfully improved ascertainment of
Table 3 Sensitivity, specificity, positive and negative predictive
values of imputation method in the Hlabisa cohort
Specificity Truly initiated ART = no
HGB/ALT +
CD4
HGB/ALT
only
Ever had an ART workup? Yes 79 84
No 35,556 35,551
Total 35,635 35,635
Specificity 99.8% 99.8%
Positive Predictive Value (PPV) Had ART workup = yes
HGB/ALT +
CD4
HGB/ALT
only
Known ART start date in 6mo
after ART workup date?
Yes 17,970 18,393
No 866 963
Total 18,836 19,329
PPV 95.4% 95.2%
Negative Predictive Value (NPV) Had ART workup = no
HGB/ALT +
CD4
HGB/ALT
only
Ever initiated ART? Yes 3009 2,521
No 35,556 35,551
Total 38,565 38,072
NPV 92.2% 93.4%
Table displays estimates in separate columns for our primary definition of ART
workup: a patient’s first haemoglobin or ALT occurring up to 12 months after
or one month before a CD4 count – and our secondary definition: first
haemoglobin or ALT, regardless of CD4 count. For sensitivity and positive
predictive value, an imputed ART start date and known start date were
considered to “match” if the imputed date occurred in the interval 5 months
and 1 week prior to and up to 3 weeks after the known ART start date.
Because we imputed by adding 21 days to the date of the lab workup, a
“match” occurred if the workup date was in the six months prior to known
start date. For specificity and negative predictive value, there was no reference
date – of initiation or lab workup – with which to define a six-month interval.
Therefore, we report specificity and NPV for whether a patient ever had
workup or initiated ART, respectively. We note that these are lower bounds for
sensitivity and NPV, which would be higher were we to assign fake dates of
initiation or workup to patients without them. Data are presented for Hlabisa
only, as pre-ART data were not systematically collected in the RTC cohort
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mortality among those on ART [26, 27]. More recently,
linkage to the South African National Cancer registry has
also been completed [28]. Imputation of treatment start
dates using the NHLS laboratory data creates a promising
additional source of “big” data for linkage opportunities.
Our results must be considered in light of their limita-
tions. First, despite the large database used, the method
was tested in just two well-resourced cohorts with well-
documented laboratory results. Though these cohorts do
represent very diverse populations and geographic re-
gions in South Africa, they may not represent all popu-
lations and regions in the national HIV program.
Additionally, changes to ART initiation protocols or
different practices in different countries would limit
the generalizability of these findings; we encourage
further validation in settings using different initiation
protocols. Researchers recently showed the potental
to impute ART start dates using laboratory-measured
repeat viral loads in New York City, where (unlike
South Africa) viral loads are assessed routinely both
before and after initiation [29]. This example illus-
trates the broad potential of lab-based imputation as
well as the necessity of tailoring imputation algo-
rithms to local clinical protocols. Second, our esti-
mates of PPV and sensitivity were computed in a
patient population known to be HIV-infected. It is
possible that implementing our approach in a popula-
tion of patients with unknown HIV status would have
a lower PPV due to the presence of false positives.
However, the requirement of a CD4 count in the pre-
vious 12 months is expected to screen out HIV-
uninfected patients and minimize false imputation of
start dates. In populations including HIV-uninfected
patients, NPV and sensitivity are expected to be much
higher than reported here. Third, the trend towards
decreasing time to initiation from workup by calendar
year may require adjustment of the 21-day interval
assumption by calendar period. Fourth, our identifica-
tion of ART workup dates relied on the ability to
identify a patient’s first ALT/HB, which requires lon-
gitudinal linkage of identifier in the national NHLS
laboratory data are currently under way by members
of this research team. Fifth, some patients may trans-
fer out of the cohort facilities after their work up and
initiate elsewhere. However, this implies that the high
PPV demonstrated in the Hlabisa cohort (95%) is ac-
tually an underestimate and that true PPV may be
even higher. Sixth, we may slightly underestimate
PPV for late 2012 as some patients may have initiated
ART after the end of the study period in December
2012 (Table S2). Lastly, if some laboratory tests were
not captured into the cohort databases, then our esti-
mates of sensitivity (82.6%, 88.2%) would also be un-
derestimates of the true values.
Conclusion
Chronic disease management in low-resource settings is typ-
ically informed by routine laboratory monitoring and guided
by standardized clinical protocols. We have demonstrated
that routine laboratory testing data can be used to impute
information about clinical decision-making that may not be
complete in patient charts or aggregate statistics. The ability
to impute ART start dates using lab workups has concrete
implications for program monitoring and patient care in the
South African national HIV CCMT program. Our focus on
one disease, one treatment decision, and one country imply
that caution should be exercised in generalizing from our re-
sults to other diseases, clinical decisions, and settings. How-
ever, our results offer a proof of concept. We are optimistic
that this analysis may illuminate other opportunities to lever-
age routinely collected laboratory data to improve the accur-
acy and completeness of clinical records and improve
chronic disease management in low resource settings in
South Africa and beyond.
Endnotes
1This adjustment factor follows directly from Bayes
Theorem, which says that PPV = sensitivity * Pr(ART)/
Pr(workup). For example: if 100 patients have a lab work-
up at a given clinic, then we expect that 95.4 of these pa-
tients will initiate ART within six months. However, those
95.4 patients represent only the 82.6% of ART initiators
who also had a workup. Dividing by 82.6% yields an esti-
mate of 115 total ART initiators at the clinic.
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Additional file 1: Table S1. Distributions of sensitivity and median days
to initiation by clinic. Table S2. Sensitivity of imputed start date and
median number of days to initiation by calendar year. Table S3. Effect of
changing the “matching” interval between ART workup and known ART
start date on sensitivity of imputation method in Hlabisa and RTC
cohorts. (DOCX 18 kb)
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